lobbying_activities: 1839344

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1839344	dd4a8429-efd7-476b-9bbb-aa946142a9cc	Q2	STANTON PARK GROUP	83717	MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY)	2016	second_quarter	MMM	Medicare, oncology, radiation and imaging reimbursement issues; Medicare physician payments; application of the sequester to cancer drug reimbursement; prompt pay discount; Oncology payment disparities in Medicare HR 2, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) H.R.2895, the Medicare Patient Access to Cancer Treatment Act of 2015 HR 6, the 21st Century Cures Act Part B Drug Reimbursement, including HR 5122 to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models	HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2016-07-11T14:59:11.810000-04:00